4,784
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies

ORCID Icon, , , ORCID Icon &
Pages 12248-12259 | Received 28 May 2021, Accepted 12 Aug 2021, Published online: 06 Sep 2021

Reprints and Permissions

Taylor & Francis does not sell reprints or permissions for this article. Please refer to the 'Licensing' tab on the article menu bar for information on the reuse conditions associated with this license type.